FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

Immune Fortifier

Immune Supportbeginner
30
Share
ペプチド

2

平均日用量mcg

479

レベル

beginner

追加

May 16, 2026

概要

The Immune Fortifier is a beginner-friendly peptide stack designed to strengthen and modulate the immune system through two complementary pathways: thymic restoration and antimicrobial defense. This protocol pairs Thymosin Alpha-1, a naturally occurring thymic peptide responsible for immune cell maturation, with LL-37, a human cathelicidin antimicrobial peptide that serves as a first-line innate defense molecule. Thymosin Alpha-1 at 1500mcg twice per week enhances T-cell differentiation, promotes dendritic cell maturation, and modulates cytokine balance between Th1 and Th2 responses. Originally isolated from thymic tissue, this peptide has been extensively studied for its ability to restore immune competence in immunocompromised individuals and has regulatory approval in over 35 countries for hepatitis and as an immune adjuvant. LL-37 at 100mcg every other day provides broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while also modulating inflammatory signaling to prevent excessive immune activation. The synergy between these peptides lies in their complementary mechanisms: Thymosin Alpha-1 strengthens adaptive immune surveillance and long-term immune memory, while LL-37 bolsters innate frontline defenses and barrier integrity. Together, they create a more robust and balanced immune response without overstimulation. Administer Thymosin Alpha-1 subcutaneously on fixed days (e.g., Monday and Thursday). LL-37 is taken every other day, ideally in the morning. Both peptides are well-tolerated with minimal reported side effects, making this an excellent entry point for those new to peptide protocols. This stack is ideal for individuals with frequent infections, seasonal immune challenges, those recovering from illness, or anyone seeking proactive immune system maintenance. Research supports Thymosin Alpha-1 as a potent immunomodulator in clinical settings, while LL-37 studies demonstrate its role in wound healing, biofilm disruption, and mucosal immunity. A standard protocol runs 4-8 weeks with reassessment.

投与プロトコル

1,500 mcg

1回の投与あたり

100 mcg

1回の投与あたり

目標と証拠

証拠ランク:community

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。